A Persistent Dementia-like Condition Following Treatment of Hepatitis C With Pegylated Interferon and Ribavirin.
作者信息
Ruffner-Statzer Susan, Bernstein Allan L
出版信息
Gastroenterol Hepatol (N Y). 2008 Jan;4(1):63-5.
Abstract
摘要
相似文献
1
A Persistent Dementia-like Condition Following Treatment of Hepatitis C With Pegylated Interferon and Ribavirin.
Gastroenterol Hepatol (N Y). 2008 Jan;4(1):63-5.
2
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390.
3
Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
J Clin Gastroenterol. 2007 Jan;41(1):111-4. doi: 10.1097/MCG.0b013e31802dd2f6.
4
Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
Clin Drug Investig. 2018 May;38(5):427-437. doi: 10.1007/s40261-018-0621-9.
5
Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Kidney Blood Press Res. 2015;40(3):258-65. doi: 10.1159/000368501. Epub 2015 May 14.
6
Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
J Clin Virol. 2014 Jul;60(3):190-5. doi: 10.1016/j.jcv.2014.04.012. Epub 2014 Apr 29.
7
Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
J Med Virol. 2016 Dec;88(12):2170-2178. doi: 10.1002/jmv.24575. Epub 2016 May 25.
8
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
BMC Gastroenterol. 2016 Aug 5;16(1):91. doi: 10.1186/s12876-016-0506-4.
9
Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
Ann Hematol. 2010 Feb;89(2):121-5. doi: 10.1007/s00277-009-0774-y. Epub 2009 Jun 30.
10
Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Drugs. 2008;68(6):791-801. doi: 10.2165/00003495-200868060-00005.
引用本文的文献
1
Cognitive impairment in hepatitis C patients on antiviral therapy.
Gastroenterol Hepatol (N Y). 2008 Jan;4(1):65-7.
本文引用的文献
1
Persistent psychosis after treatment with interferon alpha: a case report.
J Clin Psychopharmacol. 2006 Aug;26(4):446-7. doi: 10.1097/01.jcp.0000227348.59912.5d.
2
Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient.
Clin Infect Dis. 2005 Aug 1;41(3):417-9. doi: 10.1086/431769.
3
Update on chronic hepatitis C.
Clin Gastroenterol Hepatol. 2005 Jun;3(6):507-20. doi: 10.1016/s1542-3565(05)00247-8.
4
Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C.
J Int Neuropsychol Soc. 2005 Jan;11(1):16-22. doi: 10.1017/S1355617705050022.
5
Hepatitis C: a review of its neurologic complications.
Neurologist. 2002 Mar;8(2):101-6. doi: 10.1097/00127893-200203000-00004.
6
Side effects of therapy for chronic hepatitis C.
Gastroenterology. 2003 May;124(6):1711-9. doi: 10.1016/s0016-5085(03)00394-9.
7
Side effects of therapy of hepatitis C and their management.
Hepatology. 2002 Nov;36(5 Suppl 1):S237-44. doi: 10.1053/jhep.2002.36810.
8
Alterations of quantitative EEG and mini-mental state examination in interferon-alpha-treated hepatitis C.
Eur Neurol. 2002;48(2):102-7. doi: 10.1159/000062997.
9
Estimating progression to cirrhosis in chronic hepatitis C virus infection.
Hepatology. 2001 Oct;34(4 Pt 1):809-16. doi: 10.1053/jhep.2001.27831.
10
Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C.
J Interferon Cytokine Res. 2001 May;21(5):273-8. doi: 10.1089/107999001300177457.
Zotero 插件